Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ARG1 | P05089 | 5/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.39 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351910 | 1.00 | MEN1 (0.63) | MEN1BLMKMT2AARG1SLC1A2 | |
| SCHEMBL2964302 | 1.00 | MEN1 (0.63) | MEN1BLMKMT2AARG1SLC1A2 | |
| SCHEMBL17943259 | 1.00 | MEN1 (0.63) | MEN1BLMKMT2AARG1SLC1A2 | |
| SCHEMBL3260294 | 1.00 | MEN1 (0.63) | MEN1BLMKMT2AARG1SLC1A2 | |
| SCHEMBL2964298 | 1.00 | MEN1 (0.63) | MEN1BLMKMT2AARG1SLC1A2 | |
| Hydrochloric Acid SCHEMBL28578650 | 0.98 | MEN1 (0.61) | MEN1BLMKMT2AARG1SLC1A2 | |
| SCHEMBL18561419 | 0.91 | MEN1 (0.53) | MEN1BLMKMT2AARG1SLC1A2 | |
| SCHEMBL1364961 | 0.86 | — | — | |
| SCHEMBL114870 | 0.86 | — | — | |
| SCHEMBL2025245 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981984-B2 | Method for producing cis-5-hydroxy-2-piperidinecarboxylic acid derivative, and method for purifying cis-5-hydroxy-2-piperidinecarboxylic acid | API CORPORATION (JP) | 2018-05-29 | — | — | US | claimed |
| US-12286648-B2 | Engineered proline hydroxylase biocatalysts for hydroxylation of chemical compounds | CODEXIS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| EP-3469088-B1 | BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS | CODEXIS INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230272354-A1 | BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2023-08-31 | — | — | US | disclosed |
| US-11634695-B2 | Vectors for expression of biocatalysts | CODEXIS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20210032605-A1 | BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-02-04 | — | — | US | disclosed |
| US-10842784-B2 | Treatment of energy utilization disease | VIDA PHARMA LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
| US-10844358-B2 | Polynucleotides encoding biocatalysts and methods for hydroxylation of chemical compounds | CODEXIS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| EP-3469088-A1 | BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS | Codexis, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20190078061-A1 | BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2019-03-14 | — | — | US | disclosed |
| US-9512452-B2 | L-lysine hydroxylase and production method for hydroxy-L-lysine and hydroxy-L-pipecolic acid using same | API CORPORATION (JP) | 2016-12-06 | — | — | US | disclosed |
| WO-2016120890-A1 | AN ENANTIOSELECTIVE PROCESS FOR THE SYNTHESIS OF (2S,4R)-4-HYDROXYPIPECOLIC ACID | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-08-04 | — | — | WO | disclosed |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORPORATION PLC (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORPORATION PLC (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20150259715-A1 | L-Lysine Hydroxylase and Production Method for Hydroxy-L-Lysine and Hydroxy-L-Pipecolic Acid Using Same | API CORPORATION (JP) | 2015-09-17 | — | — | US | disclosed |
| US-20150239906-A1 | Method for Producing cis-5-hydroxy-2-piperidinecarboxylic Acid Derivative, and Method for Purifying cis-5-hydroxy-2-piperidinecarboxylic Acid | UBE CORPORATION (JP) | 2015-08-27 | — | — | US | disclosed |
| EP-2889378-A1 | PRODUCTION METHOD FOR L-LYSINE HYDROXYLASE AND HYDROXY-L-LYSINE USING SAME, AND PRODUCTION METHOD FOR HYDROXY-L-PIPECOLIC ACID | API Corporation (JP) | 2015-07-01 | — | — | EP | disclosed |
| EP-2889288-A1 | METHOD FOR PRODUCING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID DERIVATIVE, AND METHOD FOR PURIFYING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID | API Corporation (JP) | 2015-07-01 | — | — | EP | disclosed |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | SUMMIT CORPORATION PLC (GB) | 2011-01-20 | — | — | US | disclosed |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | SUMMIT CORPORATION PLC (GB) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | IRS1, SLC2A1, INSR | MEN1 1224/4885BLM 3369/4885KMT2A 3165/4885 |
| US-20150239906-A1 | Method for Producing cis-5-hydroxy-2-piperidinecarboxylic Acid Derivative, and Method for Purifying cis-5-hydroxy-2-piperidinecarboxylic Acid | HCAR2, HCAR1, C5 | MEN1 2863/4885BLM 4867/4885KMT2A 2367/4885 |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | IRS1, SLC2A1, INSR | MEN1 1224/4885BLM 3369/4885KMT2A 3165/4885 |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | IRS1, SLC2A1, INSR | MEN1 1224/4885BLM 3369/4885KMT2A 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.